BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28238344)

  • 21. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of pathologic response to preoperative therapy in pancreatic cancer.
    Chun YS; Cooper HS; Cohen SJ; Konski A; Burtness B; Denlinger CS; Astsaturov I; Hall MJ; Hoffman JP
    Ann Surg Oncol; 2011 Dec; 18(13):3601-7. PubMed ID: 21947697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium.
    Groen JV; Sibinga Mulder BG; van Eycken E; Valerianova Z; Borras JM; van der Geest LGM; Capretti G; Schlesinger-Raab A; Primic-Zakelj M; Ryzhov A; van de Velde CJH; Bonsing BA; Bastiaannet E; Mieog JSD
    Ann Surg Oncol; 2018 Nov; 25(12):3492-3501. PubMed ID: 30151560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.
    Chao C; Hoffman JP; Ross EA; Torosian MH; Eisenberg BL
    Am Surg; 2000 Apr; 66(4):378-85; discussion 386. PubMed ID: 10776876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort.
    Al-Husseini MJ; Saad AM; Turk T; Tabash MA; Abdel-Rahman O
    J Gastrointest Cancer; 2019 Dec; 50(4):794-800. PubMed ID: 30105523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of staging node-negative pancreas cancer: a potential quality measure.
    Tomlinson JS; Jain S; Bentrem DJ; Sekeris EG; Maggard MA; Hines OJ; Reber HA; Ko CY
    Arch Surg; 2007 Aug; 142(8):767-723; discussion 773-4. PubMed ID: 17709731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EUS and survival in patients with pancreatic cancer: a population-based study.
    Ngamruengphong S; Li F; Zhou Y; Chak A; Cooper GS; Das A
    Gastrointest Endosc; 2010 Jul; 72(1):78-83, 83.e1-2. PubMed ID: 20620274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.
    Allen PJ; Kuk D; Castillo CF; Basturk O; Wolfgang CL; Cameron JL; Lillemoe KD; Ferrone CR; Morales-Oyarvide V; He J; Weiss MJ; Hruban RH; Gönen M; Klimstra DS; Mino-Kenudson M
    Ann Surg; 2017 Jan; 265(1):185-191. PubMed ID: 27163957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymph node identification following neoadjuvant therapy in rectal cancer: A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database.
    Ecker BL; Paulson EC; Datta J; Jeganathan AN; Aarons C; Kelz RR; Mahmoud NN
    J Surg Oncol; 2015 Sep; 112(4):415-20. PubMed ID: 26250884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters.
    Baucom RB; Maguire LH; Kavalukas SL; Geiger TM; Ford MM; Muldoon RL; Hopkins MB; Hawkins AT
    Dis Colon Rectum; 2017 Dec; 60(12):1260-1266. PubMed ID: 29112561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma.
    Liu C; Cheng H; Jin K; Guo M; Lu Y; Wang Z; Yang C; Long J; Ni Q; Yu X; Luo G
    Pancreas; 2018 Jul; 47(6):742-747. PubMed ID: 29851752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Int J Surg; 2018 Apr; 52():221-228. PubMed ID: 29425826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival in pancreatic cancer: the best is yet to come.
    Sauer BG; Shami VM
    Gastrointest Endosc; 2010 Jul; 72(1):84-5. PubMed ID: 20620275
    [No Abstract]   [Full Text] [Related]  

  • 39. Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer.
    Sperti C; Gruppo M; Blandamura S; Valmasoni M; Pozza G; Passuello N; Beltrame V; Moletta L
    World J Gastroenterol; 2017 Jun; 23(24):4399-4406. PubMed ID: 28706422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie.
    Delpero JR; Boher JM; Sauvanet A; Le Treut YP; Sa-Cunha A; Mabrut JY; Chiche L; Turrini O; Bachellier P; Paye F
    Ann Surg Oncol; 2015; 22(6):1874-83. PubMed ID: 25665947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.